IN8bio, a Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies, raised $40 million by offering 4 million shares at $10, the low end of the range of $10 to $12.
The company's pipeline contains lead candidates INB-200, which is currently in a Phase 1 trial for newly diagnosed glioblastoma, and INB-100, which is currently in a Phase 1 trial for patients with leukemia undergoing hematopoietic stem cell transplantation. The company also expects to file three INDs for its pipeline candidates in the 1H22 and in 2023.
IN8bio plans to list on the Nasdaq under the symbol INAB. B. Riley Securities acted as sole bookrunner on the deal.
